病理性近视继发脉络膜新生血管抗血管内皮生长因子药物治疗后预后因素研究现状

Review of prognostic factors of anti-vascular endothelial growth factor therapy on choroidal neovascularization secondary to pathological myopia

玻璃体腔注射抗VEGF药物为目前治疗病理性近视(PM)继发脉络膜新生血管(CNV)的一线治疗方案。但因PM发展程度、人口学特征以及治疗过程等因素的差异,治疗后预后情况不尽相同。完整的椭圆体带、较小的基线病灶直径与较好的基线视力是抗VEGF药物治疗预后良好的重要预测因素,而发生脉络膜视网膜萎缩或PM相关并发症则预示预后较差。年龄、种族、光动力疗法治疗史以及治疗是否及时等因素对治疗预后的影响有待进一步研究。

For choroidal neovascularization (CNV) secondary to pathological myopia, intravitreal injection of anti-VEGF has been widely used in clinic and achieved good outcome. However, due to the differences in the demographic characteristics, stages of disease progression and treatment procedure of CNV, the prognosis of the disease is variable. Complete ellipsoid band, smaller baseline choroidal neovascularization and better baseline vision are important predictors of good outcome of anti-vascular endothelial growth factor treatment. Chorioretinal atrophy or complications related to pathologic myopia indicate a poor prognosis. The influence of age, race, previous photodynamic therapy and early treatment on the prognosis of treatment need to be further studied.